ArticleExpert opinion on drug delivery2020
PROMOTING SAFE AND EFFECTIVE USE OF AEROSOL DEVICES IN COVID-19:RISKS AND SUGGESTIONS FOR VIRAL TRANSMISSION.
Article in Expert opinion on drug delivery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Risk of Transmitting Coronavirus Disease 2019 During Nebulizer Treatment: A Systematic Review.Journal of aerosol medicine and pulmonary drug delivery · 2021Pooled it
- Exploring the Potential of PLGA Nanoparticles for Enhancing Pulmonary Drug Delivery.Molecular pharmaceutics · 2025Review
- Nebuliser therapy in critical care: The past, present and future.Journal of the Intensive Care Society · 2024Review
- Spray-Dried Inhalable Microparticles Combining Remdesivir and Ebselen against SARS-CoV-2 Infection.Pharmaceutics · 2023Article
- Pulmonary delivery of favipiravir inhalation solution for COVID-19 treatment:Drug delivery · 2022Article
- Pulmonary Procedures During the COVID-19 Pandemic: A Work Group Report of the AAAAI Asthma Diagnosis and Treatment (ADT) Interest Section.The journal of allergy and clinical immunology. In practice · 2022Article
- WAO-ARIA consensus on chronic cough - Part III: Management strategies in primary and cough-specialty care.The World Allergy Organization journal · 2022Review
- Nasally inhaled therapeutics and vaccination for COVID-19: Developments and challenges.MedComm · 2021Review
- Recent updates in COVID-19 with emphasis on inhalation therapeutics: Nanostructured and targeting systems.Journal of drug delivery science and technology · 2021Review
- Nebuliser Type Influences Both Patient-Derived Bioaerosol Emissions and Ventilation Parameters during Mechanical Ventilation.Pharmaceutics · 2021Article
- Aerosol drug delivery to tracheotomized patients with COVID-19: Pragmatic suggestions for clinicians.Canadian journal of respiratory therapy : CJRT = Revue canadienne de la therapie respiratoire : RCTR · 2021Article
- How to deliver aerosolized medications through high flow nasal cannula safely and effectively in the era of COVID-19 and beyond: A narrative review.Canadian journal of respiratory therapy : CJRT = Revue canadienne de la therapie respiratoire : RCTR · 2021Review
- Treating COPD Patients with Inhaled Medications in the Era of COVID-19 and Beyond: Options and Rationales for Patients at Home.International journal of chronic obstructive pulmonary disease · 2021Review
- Asthma and COVID-19: What do we know now.Clinical medicine insights. Circulatory, respiratory and pulmonary medicine · 2020Review
Corrections and comments
- Comment on
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
32799579What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.